Metabolic Modulation as Treatment in Acute Heart Failure (MEMO)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure
Full description
Acute heart failure is a serious disease that despite modern therapies carries a high mortality. Inotropic drugs improve patient status but yield a higher risk of death. Previous studies have shown that myocardial contractility improves when glucose fermentation is up regulated and decreases when Free Fatty Acids are high. In a placebo-controlled design we wish to shift myocardial substrate metabolism towards increased glucose uptake and utilization and measure hemodynamics and biochemical markers of metabolism and prognosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Acute heart failure
- NYHA class III - IV.
- ejection fraction <35
Exclusion criteria
- Age <18 år or >85 år,
- allergy
- renal failure
- recently developed brady- or tachy-arrythmias
- Serious infection
- Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease
- Recent Myocardial infarction (<6 Weeks)
- Pulmonary Wedge pressure >30 mm Hg
- diabetes mellitus treated with insulin
- peptic ulcer
- pregnancy
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal